Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529833 | 1.00 | MAPT (0.55) | MAPTPOLBKDM4ELMNAHPGD | |
| Acetic Acid SCHEMBL915013 | 0.94 | MAPT (0.56) | MAPTPOLBKDM4ELMNAHPGD | |
| Acetic Acid SCHEMBL915011 | 0.94 | MAPT (0.56) | MAPTPOLBKDM4ELMNAHPGD | |
| SCHEMBL4697709 | 0.89 | MAPT (0.51) | MAPTPOLBKDM4ELMNAHPGD | |
| SCHEMBL4697713 | 0.89 | MAPT (0.51) | MAPTPOLBKDM4ELMNAHPGD | |
| SCHEMBL7750411 | 0.87 | MAPT (0.71) | MAPTPOLBKDM4ELMNAHPGD | |
| SCHEMBL7750418 | 0.87 | MAPT (0.71) | MAPTPOLBKDM4ELMNAHPGD | |
| Hydrochloric Acid SCHEMBL915552 | 0.86 | MAPT (0.69) | MAPTPOLBKDM4ELMNAHPGD | |
| Hydrochloric Acid SCHEMBL915551 | 0.86 | MAPT (0.69) | MAPTPOLBKDM4ELMNAHPGD | |
| SCHEMBL398854 | 0.85 | MAPT (0.48) | MAPTPOLBKDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227927-B2 | Method of treating inflammation | ANAMAR AB (SE) | 2016-01-05 | — | — | US | claimed |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | claimed |
| EP-2411812-B1 | METABOLIC PROFILES | ANAMAR AB (SE) | 2013-10-02 | — | — | EP | claimed |
| US-8410174-B2 | Method for treating arthritis | ANAMAR AB (SE) | 2013-04-02 | — | — | US | claimed |
| US-20120190751-A1 | COMPOUNDS FOR TREATMENTS OF INFLAMMATION | ANA-MAR AB (SE) | 2012-07-26 | — | — | US | claimed |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | ANAMAR AB (SE) | 2012-07-12 | — | — | US | claimed |
| EP-2470270-A1 | COMPOUNDS FOR TREATMENT OF INFLAMMATION | AnaMar AB (SE) | 2012-07-04 | — | — | EP | claimed |
| US-20120108668-A1 | METABOLIC PROFILES | HPF IP HOLDING S.A. (LU) | 2012-05-03 | — | — | US | claimed |
| US-8148429-B2 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ANAMAR AB (SE) | 2012-04-03 | — | — | US | claimed |
| WO-2011012868-A1 | COMPOUNDS FOR TREATMENT OF INFLAMMATION | ANAMAR AB (SE) | 2011-02-03 | — | — | WO | claimed |
| WO-2008061647-A1 | USE OF A COMPOUND AS VEGF INHIBITOR | ACURE PHARMA AB (SE) | 2008-05-29 | — | — | WO | claimed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | claimed |
| EP-3310762-B1 | NOVEL 5-HT2 ANTAGONISTS | ANAMAR AB (SE) | 2020-08-05 | — | — | EP | disclosed |
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | INFLECTIS BIOSCIENCE (FR) | 2020-06-09 | — | — | US | disclosed |
| US-10544103-B2 | 5-HT2 antagonists | ANAMAR AB (SE) | 2020-01-28 | — | — | US | disclosed |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | INFLECTIS BIOSCIENCE (FR) | 2018-08-09 | — | — | US | disclosed |
| WO-2008061647-A8 | USE OF A COMPOUND AS VEGF INHIBITOR | ACURE PHARMA AB (SE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008061647-A1 | USE OF A COMPOUND AS VEGF INHIBITOR | ACURE PHARMA AB (SE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008061647-A1 | USE OF A COMPOUND AS VEGF INHIBITOR | ACURE PHARMA AB (SE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190751-A1 | COMPOUNDS FOR TREATMENTS OF INFLAMMATION | IL6, IL1B, TNF | MAPT 3564/4885POLB 3813/4885KDM4E 597/4885 |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | MC2R, MC5R, MC1R | MAPT 3465/4885POLB 3116/4885KDM4E 3363/4885 |
| US-10544103-B2 | 5-HT2 antagonists | HTR2B, HTR2C, HTR2A | MAPT 3460/4885POLB 3952/4885KDM4E 3139/4885 |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | MC5R, MC1R, MC2R | MAPT 3995/4885POLB 3257/4885KDM4E 3527/4885 |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | MGMT, GLI1, CA9 | MAPT 2729/4885POLB 3190/4885KDM4E 1292/4885 |
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | MGMT, GLI1, CA9 | MAPT 2729/4885POLB 3190/4885KDM4E 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.